Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOpredict-EGFR
NL-OMON60121Phase 2Recruiting
- Sponsor
- Universitätsmedizin Essen
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Feasibility of preoperative therapy. Started Apr 2025; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60121.